East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cephalexin For Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL. Aurobindo Pharma’s Cephalexin For Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Keflex for Oral […] The post Aurobindo Receives FDA Approval for Cephalexin For Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL appeared first on Aurobindo Pharma USA .